• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells

Posted on: Wednesday, 4 March 2009, 10:52 CST

MOUNTAIN VIEW, Calif., March 4 /PRNewswire/ -- The Healthcare practice at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the North American biopharmaceuticals market to be held on Thursday, March 5, 2009 at 10:00 a.m. PST.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The biopharmaceutical industry has witnessed healthy growth and is experiencing several notable trends, such as the increased use of contract manufacturing organizations and the targeting of biotechnology companies for mergers and acquisitions by pharmaceutical companies or other biotechnology companies. In addition, this industry faces issues that are immersed in heated debate, such as the approval pathway of biosimilars.

This briefing will benefit strategic planners, business development managers, research professionals, marketing managers, and those who are considering entering this dynamic market. Highlights of the briefing include an analysis of overall market trends, general market sizing, and a look at selected issues.

"One of the hot topics in the biopharmaceutical market is the ethical debate surrounding the research and use of embryonic stem cells," notes Frost & Sullivan Research Analyst Katheryn Symank. "This issue is immersed in both political and ethical controversy. Some argue that the use of human embryonic stem cells is unethical while others support their use because of the potential medical good to the population."

To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company email address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Contact: Stephanie Ochoa Corporate Communications - North America P: 210.247.2421 F: 210.348.1003 E: stephanie.ochoa@frost.com http://www.frost.com

SOURCE Frost & Sullivan

Source: PR Newswire

More News in this Category